Rocket Pharmaceuticals, Inc. RCKT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-02-18 |
| Shares Out. | 109,770,000 |
| Website | rocketpharma.com ↗ |
| Phone | 13026365400 |
| Employees | 202 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | $123.2M |
| Free Cash Flow | -$170.4M |
| Total Assets | $423.1M |
| Total Liabilities | $54.3M |
| Equity | $368.8M |
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Rocket Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol RCKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-11-01)